Page last updated: 2024-10-16

adenine and Parkinsonian Disorders

adenine has been researched along with Parkinsonian Disorders in 7 studies

Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19901 (14.29)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's4 (57.14)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Guo, Q1
Wang, B1
Wang, X1
Smith, WW1
Zhu, Y1
Liu, Z1
Mercado, G1
Castillo, V1
Soto, P1
López, N1
Axten, JM1
Sardi, SP1
Hoozemans, JJM1
Hetz, C1
Stasi, MA1
Minetti, P1
Lombardo, K1
Riccioni, T1
Caprioli, A1
Vertechy, M1
Di Serio, S1
Pace, S1
Borsini, F2
Fuzzati-Armentero, MT1
Cerri, S1
Levandis, G1
Ambrosi, G1
Montepeloso, E1
Antoninetti, G1
Blandini, F1
Baqi, Y1
Müller, CE1
Volpini, R1
Costa, G1
Simola, N1
Pinna, A1
Frau, L1
Wardas, J1
Khairnar, AS1
Schintu, N1
Morelli, M1
GOMIRATO, G1
HYDEN, H1
Rose, S1
Ramsay Croft, N1
Jenner, P1

Other Studies

7 other studies available for adenine and Parkinsonian Disorders

ArticleYear
Activation of Nrf2 in Astrocytes Suppressed PD-Like Phenotypes via Antioxidant and Autophagy Pathways in Rat and Drosophila Models.
    Cells, 2021, 07-21, Volume: 10, Issue:8

    Topics: Adenine; Animals; Animals, Genetically Modified; Antioxidants; Antiparkinson Agents; Astrocytes; Aut

2021
Targeting PERK signaling with the small molecule GSK2606414 prevents neurodegeneration in a model of Parkinson's disease.
    Neurobiology of disease, 2018, Volume: 112

    Topics: Adenine; Animals; Disease Models, Animal; eIF-2 Kinase; Female; Humans; Indoles; Male; Mice; Mice, I

2018
Animal models of Parkinson׳s disease: Effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535).
    European journal of pharmacology, 2015, Aug-15, Volume: 761

    Topics: Adenine; Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Antiparkinson Agents; Bas

2015
Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates L-DOPA-induced rotational behavior in a rodent model of Parkinson's disease.
    Journal of neurochemistry, 2015, Volume: 134, Issue:4

    Topics: Adenine; Animals; Drug Delivery Systems; Drug Synergism; Levodopa; Male; Neurons; Neuroprotective Ag

2015
Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease.
    Synapse (New York, N.Y.), 2011, Volume: 65, Issue:3

    Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Anti-Inflammatory Agents; Brain; Immunohistoche

2011
A BIOCHEMICAL GLIA ERROR IN THE PARKINSON DISEASE.
    Brain : a journal of neurology, 1963, Volume: 86

    Topics: Adenine; Cytosine; Globus Pallidus; Guanine; Neurochemistry; Neuroglia; Neurons; Nucleic Acids; Park

1963
The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats.
    Brain research, 2007, Feb-16, Volume: 1133, Issue:1

    Topics: Adenine; Adenosine; Adenosine A2 Receptor Antagonists; Animals; Brain; Disease Models, Animal; Dopam

2007